Fig 1: METTL3 reduces TACSTD2 mRNA stability via an m6A-YTHDC2-dependent signaling. A: Prediction of m6A sites of TACSTD2 by SRAMP database. B: Analyzing m6A modification sites in the TACSTD2 coding sequence region through database. C: METTL3 expression level of THCA in GEPIA2 databases. D: RT-qPCR was used to evaluate the mRNA level adjusted to GAPDH of methyltransferases and demethylases in THCA and paired tissues. The expression levels of TACSTD2 in METTL3-overexpressing and METTL3 knockdown PTC cells were detected by WB (E) and qRT-PCR (F). G: MeRIP-qPCR analysis was employed to demonstrate METTL3-mediated TACSTD2 m6A modifications. The m6A modification of TACSTD2 was increased on upregulation of METTL3, while it was depleted on METTL3 silencing. H-I: TACSTD2 mRNA level in METTL3-overexpressing PTC cells treated with actinomycin D at the indicated time points were detected by qRT-PCR. METTL3 overexpression reduced the half-life of TACSTD2 transcript. J: YTHDC2 expression level of THCA in GEPIA2 databases. K: RT-qPCR was used to evaluate the mRNA level adjusted to GAPDH of N6-methyladenosine readers in THCA and paired tissues. L: The expression levels of TACSTD2 in YTHDC2-overexpressing PTC cells were detected by qRT-PCR. M: The expression levels of TACSTD2 in YTHDC2-overexpressing and YTHDC2 knockdown PTC cells were detected by WB. N: RIP-qPCR evaluated enrichment level of TACSTD2 in PTC cells after YTHDF2 knockdown. O: TACSTD2 mRNA level in YTHDC2 overexpression PTC cells treated with actinomycin D at the indicated time points were detected by qRT-PCR. YTHDC2 overexpression reduced the half-life of TACSTD2 transcript. P: WB was used to assess TACSTD2 level in PTC cells transfected with NC or OE-METTL3 with sh-NC or sh-YTHDC2.